VLGC Virologic (MM)

ViroLogic Announces the Promotion of Michael Bates, M.D., to Vice President of Clinical Research SOUTH SAN FRANCISCO, Calif., June 22 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced today that Michael Bates, M.D., has been promoted to the position of Vice President, Clinical Research. Dr. Bates will manage the Company's clinical programs and will report directly to Chairman and CEO Bill Young. "Mike serves as a driving force of our clinical research program and a key contributor to our physician education initiatives, chairing Drug Resistance Forums and presenting to the HIV physician community. He has made many important contributions to ViroLogic as a collaborator with academic institutions and life sciences companies," said Bill Young. "Mike is a true visionary who firmly believes in personalized medicine. In his new role, Mike will be able to build on his accomplishments in HIV and apply his understanding of disease management and immunology as ViroLogic expands into other diseases." Dr. Bates joined the Clinical Research group at ViroLogic, Inc., as Medical Director in January 2001 and was promoted to Senior Director in 2003. Previously, Dr. Bates served as Regional Medical Director/Medical Liaison for Roche, focusing on virology. Dr. Bates completed his internship and residency in Internal Medicine at the University of California, San Francisco, before pursuing fellowship training in Cardiology at Duke University in Durham, North Carolina, and in Infectious Diseases at the University of Washington in Seattle, Washington. About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at http://www.virologic.com/. Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, whether ViroLogic successfully introduces new products, whether others introduce competitive products, the risk that the Company's products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic's products or services, whether the Company will encounter problems or delays in automating its processes, whether intellectual property underlying the Company's PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson, CFO of ViroLogic, +1-650-624-4164, or Web site: http://www.virologic.com/

Copyright